Greenphire expands ConneX patient service solution

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/monkeybusinessimages)
(Image: Getty/monkeybusinessimages)

Related tags: Clinical trials, COVID-19, Greenphire, Coronavirus

The company’s ConneX Patient Direct service enables transport of trial medications, equipment and healthcare professionals directly to participants.

The Patient Direct service is designed to enable sites and sponsors to continue trials in the face of disruptive events, such as the current COVID-19 pandemic. It enables ‘clean’ transport for needed medications, medical equipment and staff for treatment and monitoring.

The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) both have issued guidelines for conducting clinical trials during the spread of the virus. The guidelines empower sponsors to explore alternative methods and ways to ensure the continued safety of participants and staff.

Continuing trials

Jim Murphy, Greenphire CEO, told Outsourcing-Pharma that the existing ConneX patient travel service served trials well, in enabling transport of patients to a clinic for trial activity, then safely back home. The COVID-19 pandemic, however, disrupted the typical flow of participants.

As the pandemic spread, it became very clear that medically fragile patients were unable to go to clinical trial sites​,” he told us. "Through conversations with sponsors and sites, as well as in our 1,800+ person site survey and recent FDA/EMA guidance, it was clear that new stresses have emerged, and that existing travel patterns and services don’t meet the needs of today’s challenging environment​.”

Site survey

The company developed the Patient Direct service in response to the survey, which polled site personnel across the globe on the impact of COVID-19. Findings of the survey include:

  • 69% of survey respondents are using technology to support at-home patient care.
  • 60% would use a service that would transport medical equipment and/or medicine to the patient’s home.
  • Almost 48% would find a service that would facilitate the travel of site personnel to patients’ homes to conduct regularly scheduled visits useful.
  • Nearly 55% are open to patients going to an alternative, closer facility for tests or visits in an effort to keep the patients in the trial.

Additionally, one respondent, when asked what their site was doing to help meet patient needs, indicated staff were conducting telephone monitoring, medical accompaniment of the research subjects, and traveling to participant homes to collect samples and deliver medication.

I live nearby an elder patient and did not want them to travel by bus because of potential contact with infected commuters​,” the respondent indicated. “I transported the patient in my car​.”

Addressing concerns

Murphy told us the ConneX Patient Direct service helps address the needs and concerns expressed by site personnel by making it possible to safely send medicines, equipment and site team members to participants’ residences.

This globally available service can also support traditional visit flows involving patients traveling to the clinic but does so using medical grade clean ground transportation​,” he said. “This new flow of travel keeps the patient, site and study on-track by ensuring treatments are available to the patients who depend on them​.”

Murphy indicated Patient Direct is a permanent addition to the ConneX service suite. He added such direct-to-patient services can serve as an effective addition to decentralized trials and telemedicine trial programs.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars